vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v24i3.2918vsp-3777Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWЯзвенный колит и болезнь Крона в детском возрасте: актуальные вопросы и решенияUcerative Colitis and Crohn’s Disease in Childhood: Topical Issues and Solutionshttps://orcid.org/0000-0002-6837-9753АракелянА. Л.ArakelyanAnna L.

Аракелян Анна Левоновна - врач-гастроэнтеролог отделения гастроэнтерологии для детей, научный сотрудник отдела научных основ детской гастроэнтерологии, гепатологии и метаболических нарушений.

117593, Москва, Литовский бул., д. 1А

Moscow

doc.arakelyan@mail.ruhttps://orcid.org/0000-0002-3697-4283СурковА. Н.SurkovAndrey N.

Москва

Moscow

https://orcid.org/0000-0001-5549-857XБессоновЕ. Е.BessonovEvgeny E.

Москва

Moscow

https://orcid.org/0000-0001-6152-5693СытьковВ. В.SytkovValentin V.

Москва

Moscow

https://orcid.org/0009-0004-1751-1293ГетмановС. Д.GetmanovStanislav D.

Москва

Moscow

https://orcid.org/0009-0008-0449-2053ФатуллаевС. Т.FatullaevSadig T.

Москва

Moscow

https://orcid.org/0009-0005-8188-9589ИзотоваН. А.IzotovaNataly A.

Москва

Moscow

https://orcid.org/0009-0004-4114-8236МалякинаА. Д.MalyakinaAlina D.

Москва

Moscow

https://orcid.org/0009-0004-5551-8576ВласоваЗ. Е.VlasovaZlata E.

Москва

Moscow

https://orcid.org/0009-0007-8349-4286ИльяшенкоЕ. Н.Il’yashenkoElizaveta N.

Москва

Moscow

НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationРоссийский Университет Медицины; Федеральный научно-клинический центр детей и подростковРоссияRussian University of Medicine; Federal Clinical Research Centre of Children and AdolescentsRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияPirogov Russian National Research Medical UniversityRussian Federation202521072025243146156Copyright © Аракелян А.Л., Сурков А.Н., Бессонов Е.Е., Сытьков В.В., Гетманов С.Д., Фатуллаев С.Т., Изотова Н.А., Малякина А.Д., Власова З.Е., Ильяшенко Е.Н., 20252025Аракелян А.Л., Сурков А.Н., Бессонов Е.Е., Сытьков В.В., Гетманов С.Д., Фатуллаев С.Т., Изотова Н.А., Малякина А.Д., Власова З.Е., Ильяшенко Е.Н.Arakelyan A.L., Surkov A.N., Bessonov E.E., Sytkov V.V., Getmanov S.D., Fatullaev S.T., Izotova N.A., Malyakina A.D., Vlasova Z.E., Il’yashenko E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3777

Воспалительные заболевания кишечника (ВЗК) у детей представляют собой гетерогенную группу хронических заболеваний, характеризующихся рецидивирующим воспалением различных отделов желудочно-кишечного тракта. В последние десятилетия отмечается неуклонный рост заболеваемости ВЗК в педиатрической популяции. Наиболее распространенными формами ВЗК являются болезнь Крона и язвенный колит. Диагностика ВЗК у детей представляет значительные трудности в связи с неспецифичностью клинических проявлений и необходимостью проведения комплексного обследования, включающего эндоскопические, гистологические и лучевые методы. Современные подходы к лечению ВЗК у детей направлены на достижение и поддержание ремиссии, предотвращение осложнений и повышение качества жизни пациентов. Однако, несмотря на значительные успехи в диагностике и терапии ВЗК у детей, проблема остается актуальной. В обзоре представлены современные данные об эпидемиологии, течении и результатах применения терапевтических и хирургических стратегий в лечении ВЗК у детей.

Inflammatory bowel disease (IBD) in children is a heterogeneous group of chronic diseases characterized by recurrent inflammation of various parts of gastrointestinal tract. Steady increase in the IBD incidence in pediatric population has been noted in recent decades. The most common forms of IBD are Crohn’s disease and ulcerative colitis. IBD diagnosis in children is challenging due to non-specific clinical signs and need for comprehensive examination, including endoscopic, histological, and imaging methods. Modern approaches to IBD management in children are focused on achieving and maintaining remission, preventing complications, and improving patients quality of life. However, despite significant advances in IBD diagnosis and treatment in children, the problem remains topical. This review presents current data on epidemiology, course, and outcomes of therapeutic and surgical strategies in IBD management in children.

воспалительные заболевания кишечникаязвенный колитболезнь Кронадиагностикатерапияinflammatory bowel diseaseucerative colitisCrohn’s diseasediagnosismanagementReferencesBruner LP, White AM, Proksell S. Inflammatory Bowel Disease. Prim Care. 2023;50(3):411-427. doi: https://doi.org/10.1016/j.pop.2023.03.009Bruner LP, White AM, Proksell S. Inflammatory Bowel Disease. Prim Care. 2023;50(3):411-427. doi: https://doi.org/10.1016/j.pop.2023.03.009Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022;10(10):1047-1053. doi: https://doi.org/10.1002/ueg2.12319Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022;10(10):1047-1053. doi: https://doi.org/10.1002/ueg2.12319Стамболцян В.Ш., Бакулин И.Г., Асланов Б.И., Кириллова А.А. Воспалительные заболевания кишечника: эпидемиология и факторы риска (обзор литературы) // Колопроктология. — 2024. — Т. 23. — № 4. — С. 148-158. — doi: https://doi.org/10.33878/2073-7556-2024-23-4-148-158Stambolcyan VSh, Bakulin IG, Aslanov BI, Kirillova AA. Inflammatory Bowel Diseases: Epidemiology and Risk Factors (Literature Review). Koloproktologiya. 2024;23(4):148-158. (In Russ). doi: https://doi.org/10.33878/2073-7556-2024-23-4-148-158Fuller MK. Pediatric Inflammatory Bowel Disease: Special Considerations. Surg Clin N Am. 2019;99(6):1177-1183. doi: https://doi.org/10.1016/j.suc.2019.08.008Fuller MK. Pediatric Inflammatory Bowel Disease: Special Considerations. Surg Clin N Am. 2019;99(6):1177-1183. doi: https://doi.org/10.1016/j.suc.2019.08.008Khalili H. The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down. Inflamm Bowel Dis. 2020;26(4):591-592. doi: https://doi.org/10.1093/ibd/izz186Khalili H. The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down. Inflamm Bowel Dis. 2020;26(4):591-592. doi: https://doi.org/10.1093/ibd/izz186Khan R, Kuenzig ME, Benchimol EI. Epidemiology of Pediatric Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023;52(3):483-496. doi: https://doi.org/10.1016/j.gtc.2023.05.001Khan R, Kuenzig ME, Benchimol EI. Epidemiology of Pediatric Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023;52(3):483-496. doi: https://doi.org/10.1016/j.gtc.2023.05.001Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology. 2022;162(4):1147-1159.e4. doi: https://doi.org/10.1053/j.gastro.2021.12.282Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology. 2022;162(4):1147-1159.e4. doi: https://doi.org/10.1053/j.gastro.2021.12.282Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010;157(2):233-239.e1. doi: https://doi.org/10.1016/j.jpeds.2010.02.024Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010;157(2):233-239.e1. doi: https://doi.org/10.1016/j.jpeds.2010.02.024Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-122. doi: https://doi.org/10.25122/jml-2018-0075Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-122. doi: https://doi.org/10.25122/jml-2018-0075Хавкин А.И., Налетов А.В., Марченко Н.А. Воспалительные заболевания кишечника у детей: современные достижения в диагностике и терапии // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2023. — Т. 33. — № 6. — С. 7-15. — doi: https://doi.org/10.22416/1382-4376-2023-33-6-7-15Khavkin AI, Nalyotov AV, Marchenko NA. Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):7-15. (In Russ). doi: https://doi.org/10.22416/1382-4376-2023-33-6-7-15Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146(1):35-40. doi: https://doi.org/10.1016/j.jpeds.2004.08.043Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146(1):35-40. doi: https://doi.org/10.1016/j.jpeds.2004.08.043Князев О.В., Шкурко Т.В., Каграманова А.В. и др. Эпидемиология воспалительных заболеваний кишечника. Современное состояние проблемы (обзор литературы) // Доказательная гастроэнтерология. — 2020. — Т. 9. — № 2. — С. 66-73. — doi: https://doi.org/10.17116/dokgastro2020902166Knyazev OV, Shkurko TV, Kagramanova AV, et al. Epidemiology of inflammatory bowel disease. State of the problem (review). Russian Journal of Evidence-based Gastroenterology = Dokazatel'naya gastroenterologiya. 2020;9(2):66-73. (In Russ). doi: https://doi.org/10.17116/dokgastro2020902166Плотникова Е.Ю., Чашкова Е.Ю. Некоторые аспекты лечения воспалительных заболеваний кишечника // Лечащий врач. — 2019. — № 8. — С. 14-20.Plotnikova E.Yu., Chashkova E.Yu. Some aspects of treating inflammatory intestinal diseases. Lechaschii Vrach. 2019;(8):14-20. (In Russ).Ashton JJ, Barakat FM, Barnes C, et al. Incidence and Prevalence of Paediatric Inflammatory Bowel Disease Continues to Increase in the South of England. J Pediatr Gastroenterol Nutr. 2022;75(2):e20-e24. doi: https://doi.org/10.1097/MPG.0000000000003511Ashton JJ, Barakat FM, Barnes C, et al. Incidence and Prevalence of Paediatric Inflammatory Bowel Disease Continues to Increase in the South of England. J Pediatr Gastroenterol Nutr. 2022;75(2):e20-e24. doi: https://doi.org/10.1097/MPG.0000000000003511Torres J, Gomes C, Jensen CB, et al. Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD. J Crohns Colitis. 2023;17(1):30-36. doi: https://doi.org/10.1093/ecco-jcc/jjac111Torres J, Gomes C, Jensen CB, et al. Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD. J Crohns Colitis. 2023;17(1):30-36. doi: https://doi.org/10.1093/ecco-jcc/jjac111Jarmakiewicz-Czaja S, Zielinska M, Sokal A, Filip R. Genetic and Epigenetic Etiology of Inflam matory Bowel Disease: An Update. Genes (Basel). 2022;13(12):2388. doi: https://doi.org/10.3390/genes13122388Jarmakiewicz-Czaja S, Zielinska M, Sokal A, Filip R. Genetic and Epigenetic Etiology of Inflam matory Bowel Disease: An Update. Genes (Basel). 2022;13(12):2388. doi: https://doi.org/10.3390/genes13122388Vatn MH, Sandvik AK. Inflammatory bowel disease. Scand J Gastroenterol. 2015;50(6):748-762. doi: https://doi.org/10.3109/00365521.2015.1033000Vatn MH, Sandvik AK. Inflammatory bowel disease. Scand J Gastroenterol. 2015;50(6):748-762. doi: https://doi.org/10.3109/00365521.2015.1033000Glick SR, Carvalho RS. Inflammatory bowel disease. Pediatr Rev. 2011;32(1):14-24; quiz 25. doi: https://doi.org/10.1542/pir.32-1-14Glick SR, Carvalho RS. Inflammatory bowel disease. Pediatr Rev. 2011;32(1):14-24; quiz 25. doi: https://doi.org/10.1542/pir.32-1-14Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-753. doi: https://doi.org/10.1136/gut.2005.082909Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-753. doi: https://doi.org/10.1136/gut.2005.082909Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. doi: https://doi.org/10.1097/MPG.0000000000000239Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. doi: https://doi.org/10.1097/MPG.0000000000000239Ström A, Jansson S, Wewer MD, et al. Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes. Clin Gastroenterol Hepatol. 2025:S1542-3565(25)00492-6. doi: https://doi.org/10.1016/j.cgh.2025.05.015Ström A, Jansson S, Wewer MD, et al. Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes. Clin Gastroenterol Hepatol. 2025:S1542-3565(25)00492-6. doi: https://doi.org/10.1016/j.cgh.2025.05.015Mann-Jimenez I, Gomollon F. Year 2005: Clinical, serological and molecular classification of inflammatory bowel disease. Gastroenterol Hepatol. 2020;43(7):383-384. doi: https://doi.org/10.1016/j.gastrohep.2020.02.010Mann-Jimenez I, Gomollon F. Year 2005: Clinical, serological and molecular classification of inflammatory bowel disease. Gastroenterol Hepatol. 2020;43(7):383-384. doi: https://doi.org/10.1016/j.gastrohep.2020.02.010Echarri Piudo A. Inflammatory bowel disease — Newer models of care. Rev Esp Enferm Dig. 2019;111(8):577-578. doi: https://doi.org/10.17235/reed.2019.6495/2019Echarri Piudo A. Inflammatory bowel disease — Newer models of care. Rev Esp Enferm Dig. 2019;111(8):577-578. doi: https://doi.org/10.17235/reed.2019.6495/2019Singeap AM, Sfarti C, Girleanu I, et al. Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy. Medicina (Kaunas). 2023;59(12):2064. doi: https://doi.org/10.3390/medicina59122064Singeap AM, Sfarti C, Girleanu I, et al. Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy. Medicina (Kaunas). 2023;59(12):2064. doi: https://doi.org/10.3390/medicina59122064Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis. 2020;14(2):155-168. doi: https://doi.org/10.1093/ecco-jcc/jjz187Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis. 2020;14(2):155-168. doi: https://doi.org/10.1093/ecco-jcc/jjz187Бельмер С.В., Разумовский А.Ю., Хавкин А.И. Детская гастроэнтерология: национальное руководство. — М.: ГЭОТАР-Медиа; 2022. — 864 с.Bel'mer SV, Razumovskii AYu, Khavkin AI. Detskaya gastroenterologiya: National Guidelines. Moscow: GEOTAR-Media; 2022. 864 p.Gordon IO, Abushamma S, Kurowski JA, et al. Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation. J Crohns Colitis. 2022;16(5):804-821. doi: https://doi.org/10.1093/ecco-jcc/jjab216Gordon IO, Abushamma S, Kurowski JA, et al. Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation. J Crohns Colitis. 2022;16(5):804-821. doi: https://doi.org/10.1093/ecco-jcc/jjab216Cucinotta U, Arrigo S, Dipasquale V, et al. Clinical Course of Very Early-Onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(5):590-595. doi: https://doi.org/10.1097/MPG.0000000000003730Cucinotta U, Arrigo S, Dipasquale V, et al. Clinical Course of Very Early-Onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(5):590-595. doi: https://doi.org/10.1097/MPG.0000000000003730Rubalcava NS, Gadepalli SK. Inflammatory Bowel Disease in Children and Adolescents. Adv Pediatr. 2021;68:121-142. doi: https://doi.org/10.1016/j.yapd.2021.05.005Rubalcava NS, Gadepalli SK. Inflammatory Bowel Disease in Children and Adolescents. Adv Pediatr. 2021;68:121-142. doi: https://doi.org/10.1016/j.yapd.2021.05.005Ганджалян Д.А., Вафина А.Р., Датхужева Д.А. Неспецифический язвенный колит среди детей. Этиопатогенез и лечение // Инновации. Наука. Образование. — 2022. — № 62. — С. 56-70.Gandzhalyan DA, Vafina AR, Dathuzheva DA. Nespetsificheskii yazvennyi kolit sredi detei. Etiopatogenez i lechenie. Innovacii. Nauka. Obrazovanie. 2022;(62):56-70. (In Russ).Назаренко О.Н., Кастюкевич Л.И., Горная Н.Н. и др. Диагностика и лечение язвенного колита у детей // Педиатрия. Восточная Европа. — 2021. — Т. 9. — № 4. — С. 634-651. — doi: https://doi.org/10.34883/PI.2021.9.4.011Nazarenko ON, Kastyukevich LI, Gornaya NN, et al. Diagnosis and Treatment of Ulcerative Colitis in Children. Pediatrics. Eastern Europe. 2021;9(4):634-651. (In Russ). doi: https://doi.org/10.34883/PI.2021.9.4.011Qin X. Why is damage limited to the mucosa in ulcerative colitis but transmural in Crohn's disease? World J Gastrointest Pathophysiol. 2013;4(3):63-64. doi: https://doi.org/10.4291/wjgp.v4.i3.63Qin X. Why is damage limited to the mucosa in ulcerative colitis but transmural in Crohn's disease? World J Gastrointest Pathophysiol. 2013;4(3):63-64. doi: https://doi.org/10.4291/wjgp.v4.i3.63Самолыго И.С., Аминова А.И., Ерюшова Т.Ю. и др. Необычное начало и течение болезни Крона у детей // Экспериментальная и клиническая гастроэнтерология. — 2024. — № 6. — С. 221-224. — doi: https://doi.org/10.31146/1682-8658-ecg-226-6-221-224Samolygo IS, Aminova AI, Eryushova TYu, et al. Unusual Onset and Course of Crohn's Disease in Children. Experimental and Clinical Gastroenterology. 2024;(6):221-224. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-226-6-221-224Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric Inflammatory Bowel Disease. Pediatrics. 2023;151(1):e2022058037. doi: https://doi.org/10.1542/peds.2022-058037Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric Inflammatory Bowel Disease. Pediatrics. 2023;151(1):e2022058037. doi: https://doi.org/10.1542/peds.2022-058037Яблокова Е.А., Горелов А.В., Сичинава И.В. и др. Течение внекишечных проявлений воспалительных заболеваний кишечника у детей // Экспериментальная и клиническая гастроэнтерология. — 2016. — № 8. — С. 62-66.Yablokova EA, Gorelov AV, Sichinava IV, et al. For extraintestinal manifestations of infl ammatory bowel disease in children. Experimental and Clinical Gastroenterology. 2016;(8):62-66. (In Russ).Kamel AY, Johnson ZD, Hernandez I, et al. Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis. Eur J Gastroenterol Hepatol. 2024;36(10):1186-1192. doi: https://doi.org/10.1097/MEG.0000000000002821Kamel AY, Johnson ZD, Hernandez I, et al. Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis. Eur J Gastroenterol Hepatol. 2024;36(10):1186-1192. doi: https://doi.org/10.1097/MEG.0000000000002821Hommel KA, Ramsey RR, Gray WN, Denson LA. Digital Therapeutic Self-Management Intervention in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(1):38-42. doi: https://doi.org/10.1097/MPG.0000000000003623Hommel KA, Ramsey RR, Gray WN, Denson LA. Digital Therapeutic Self-Management Intervention in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(1):38-42. doi: https://doi.org/10.1097/MPG.0000000000003623Collen LV, Snapper SB, Gordon RJ. Vertebral Compression Fractures in Very Early Onset Inflammatory Bowel Disease. JPGN Rep. 2023;4(1):e283. doi: https://doi.org/10.1097/PG9.0000000000000283Collen LV, Snapper SB, Gordon RJ. Vertebral Compression Fractures in Very Early Onset Inflammatory Bowel Disease. JPGN Rep. 2023;4(1):e283. doi: https://doi.org/10.1097/PG9.0000000000000283Attauabi M, Madsen GR, Holm JP, et al. Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study. Inflamm Bowel Dis. 2025:izaf063. doi: https://doi.org/10.1093/ibd/izaf063Attauabi M, Madsen GR, Holm JP, et al. Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study. Inflamm Bowel Dis. 2025:izaf063. doi: https://doi.org/10.1093/ibd/izaf063Wang M, Shi J, Yu C, et al. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Front Immunol. 2023;14:1298186. doi: https://doi.org/10.3389/fimmu.2023.1298186Wang M, Shi J, Yu C, et al. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Front Immunol. 2023;14:1298186. doi: https://doi.org/10.3389/fimmu.2023.1298186Bernardo D, Raimundo Fernandes S, Araujo Correia L. Treat to target in inflammatory bowel disease-a survey of treatment strategies amongst Portuguese doctors. Rev Esp Enferm Dig. 2019;111(8):593-597. doi: https://doi.org/10.17235/reed.2019.6029/2018Bernardo D, Raimundo Fernandes S, Araujo Correia L. Treat to target in inflammatory bowel disease-a survey of treatment strategies amongst Portuguese doctors. Rev Esp Enferm Dig. 2019;111(8):593-597. doi: https://doi.org/10.17235/reed.2019.6029/2018Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi: https://doi.org/10.1053/j.gastro.2020.12.031Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi: https://doi.org/10.1053/j.gastro.2020.12.031Brunet-Houdard S, Monmousseau F, Berthon G, et al. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. Scand J Gastroenterol. 2022;57(11):1312-1320. doi: https://doi.org/10.1080/00365521.2022.2085057Brunet-Houdard S, Monmousseau F, Berthon G, et al. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. Scand J Gastroenterol. 2022;57(11):1312-1320. doi: https://doi.org/10.1080/00365521.2022.2085057Casellas F, Navarro E, Amil P, et al. Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2019;111(8):586-592. doi: https://doi.org/10.17235/reed.2019.6298/2019Casellas F, Navarro E, Amil P, et al. Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2019;111(8):586-592. doi: https://doi.org/10.17235/reed.2019.6298/2019Iacucci M, Parigi TL, Del Amor R, et al. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis. Gastroenterology. 2023;164(7):1180-1188.e2. doi: https://doi.org/10.1053/j.gastro.2023.02.031Iacucci M, Parigi TL, Del Amor R, et al. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis. Gastroenterology. 2023;164(7):1180-1188.e2. doi: https://doi.org/10.1053/j.gastro.2023.02.031Wang K, Huang L, Huang W, et al. Predictive Value of CT Enterography Index for Postoperative Intra-abdominal Septic Complications in Patients With Crohn's Disease: Implications for Surgical Decision-Making. Dis Colon Rectum. 2021;64(8):964-976. doi: https://doi.org/10.1097/DCR.0000000000001796Wang K, Huang L, Huang W, et al. Predictive Value of CT Enterography Index for Postoperative Intra-abdominal Septic Complications in Patients With Crohn's Disease: Implications for Surgical Decision-Making. Dis Colon Rectum. 2021;64(8):964-976. doi: https://doi.org/10.1097/DCR.0000000000001796Хавкин А.И., Налетов А.В., Мацынина М.А. Противовоспалительные эффекты оливкового масла и его компонентов. Перспективы применения в лечении воспалительных заболеваний кишечника // Педиатрическая фармакология. — 2024. — Т. 21. — № 3. — С. 249-255. — doi: https://doi.org/10.15690/pf.v21i3.2754Khavkin AI, Nalyotov AV, Matsynina MA. Anti-inflammatory Effects of Olive Oil and Its Components. Prospects of Application in the Treatment of Inflammatory Bowel Diseases. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2024;21(3):249-255. (In Russ). doi: https://doi.org/10.15690/pf.v21i3.2754Cox SR, Lindsay JO, Fromentin S, et al. Effects of Low-FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology. 2020;158(1):176-188.e7. doi: https://doi.org/10.1053/j.gastro.2019.09.024Cox SR, Lindsay JO, Fromentin S, et al. Effects of Low-FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology. 2020;158(1):176-188.e7. doi: https://doi.org/10.1053/j.gastro.2019.09.024Chicco F, Magri S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1-9. doi: https://doi.org/10.1093/ibd/izaa097Chicco F, Magri S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1-9. doi: https://doi.org/10.1093/ibd/izaa097LaRussa T, Oliverio M, Suraci E, et al. Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. Nutrients. 2017;9(4):391. doi: https://doi.org/10.3390/nu9040391LaRussa T, Oliverio M, Suraci E, et al. Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. Nutrients. 2017;9(4):391. doi: https://doi.org/10.3390/nu9040391Cardeno A, Sanchez-Hidalgo M, Aparicio-Soto M, Alarcon-De-La-Lastra C. Unsaponifiable fraction from extra virgin olive oil inhibits the inflammatory response in LPS-activated murine macrophages. Food Chem. 2014;147:117-123. doi: https://doi.org/10.1016/j.foodchem.2013.09.117Cardeno A, Sanchez-Hidalgo M, Aparicio-Soto M, Alarcon-De-La-Lastra C. Unsaponifiable fraction from extra virgin olive oil inhibits the inflammatory response in LPS-activated murine macrophages. Food Chem. 2014;147:117-123. doi: https://doi.org/10.1016/j.foodchem.2013.09.117Vezza T, Algieri F, Rodnguez-Nogales A, et al. Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Mol Nutr Food Res. 2017;61(10):1601066. doi: https://doi.org/10.1002/mnfr.201601066Vezza T, Algieri F, Rodnguez-Nogales A, et al. Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Mol Nutr Food Res. 2017;61(10):1601066. doi: https://doi.org/10.1002/mnfr.201601066Lopez de las Hazas MC, Pinol C, Macia A, Motilva MJ. Hydroxytyrosol and the Colonic Metabolites Derived from Virgin Olive Oil Intake Induce Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. J Agric Food Chem. 2017;65(31):6467-6476. doi: https://doi.org/10.1021/acs.jafc.6b04933Lopez de las Hazas MC, Pinol C, Macia A, Motilva MJ. Hydroxytyrosol and the Colonic Metabolites Derived from Virgin Olive Oil Intake Induce Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. J Agric Food Chem. 2017;65(31):6467-6476. doi: https://doi.org/10.1021/acs.jafc.6b04933Hu J, Chen W, Zhu R, et al. Dietary risk factors in Crohn's disease and ulcerative colitis: a cohort study with paired healthy relatives as controls. Eur J Nutr. 2025;64(3):123. doi: https://doi.org/10.1007/s00394-025-03598-wHu J, Chen W, Zhu R, et al. Dietary risk factors in Crohn's disease and ulcerative colitis: a cohort study with paired healthy relatives as controls. Eur J Nutr. 2025;64(3):123. doi: https://doi.org/10.1007/s00394-025-03598-wMasip E, Donat E, Polo Miquel B, Ribes-Koninckx C. Bone mineral density in Spanish children at the diagnosis of inflammatory bowel disease. Arch Osteoporos. 2021;16(1):96. doi: https://doi.org/10.1007/s11657-021-00945-2Masip E, Donat E, Polo Miquel B, Ribes-Koninckx C. Bone mineral density in Spanish children at the diagnosis of inflammatory bowel disease. Arch Osteoporos. 2021;16(1):96. doi: https://doi.org/10.1007/s11657-021-00945-2Ahn MB, Yoo IH. Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease. Nutrients. 2023;15(24):5048. doi: https://doi.org/10.3390/nu15245048Ahn MB, Yoo IH. Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease. Nutrients. 2023;15(24):5048. doi: https://doi.org/10.3390/nu15245048Хавкин А.И., Богданова Н.М., Налетов А.В. и др. Воспалительные заболевания кишечника и молочные продукты // Педиатрическая фармакология. — 2024. — Т. 21. — № 5. — С. 455-461. — doi: https://doi.org/10.15690/pf.v21i5.2800Khavkin AI, Bogdanova NM, Nalyotov AV, et al. Inflammatory Bowel Diseases and Dairy Products. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2024;21(5):455-461. (In Russ). doi: https://doi.org/10.15690/pf.v21i5.2800Scazzocchio B, Minghetti L, D'Archivio M. Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin. Nutrients. 2020;12(9):2499. doi: https://doi.org/10.3390/nu12092499Scazzocchio B, Minghetti L, D'Archivio M. Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin. Nutrients. 2020;12(9):2499. doi: https://doi.org/10.3390/nu12092499Хавкин А.И., Налетов А.В. Куркумин — новое направление дополнительной терапии язвенного колита // Педиатрическая фармакология. — 2024. — Т. 21. — № 6. — С. 534-538. — doi: https://doi.org/10.15690/pf.v21i6.2840Khavkin AI, Nalyotov AV. Curcumin as a Novel Trend in Adjunctive Therapy for Ulcerative Colitis. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2024;21(6):534-538. (In Russ). doi: https://doi.org/10.15690/pf.v21i6.2840Yin J, Wei L, Wang N, et al. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. J Ethnopharmacol. 2022;289:115041. doi: https://doi.org/10.1016/j.jep.2022.115041Yin J, Wei L, Wang N, et al. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. J Ethnopharmacol. 2022;289:115041. doi: https://doi.org/10.1016/j.jep.2022.115041Zhao H, Li J, Zhao J, et al. Antioxidant effects of compound walnut oil capsule in mice aging model induced by D-galactose. Food Nutr Res. 2018:62. doi: https://doi.org/10.29219/fnr.v62.1371Zhao H, Li J, Zhao J, et al. Antioxidant effects of compound walnut oil capsule in mice aging model induced by D-galactose. Food Nutr Res. 2018:62. doi: https://doi.org/10.29219/fnr.v62.1371Li L, Wang S, Zhang T, et al. Walnut peptide alleviates obesity, inflammation and dyslipidemia in mice fed a high-fat diet by modulating the intestinal flora and metabolites. Front Immunol. 2023;14:1305656. doi: https://doi.org/10.3389/fim-mu.2023.1305656Li L, Wang S, Zhang T, et al. Walnut peptide alleviates obesity, inflammation and dyslipidemia in mice fed a high-fat diet by modulating the intestinal flora and metabolites. Front Immunol. 2023;14:1305656. doi: https://doi.org/10.3389/fim-mu.2023.1305656Miao F, Shan C, Shah SA, et al. D. Effect of walnut (Juglans sigillata) oil on intestinal antioxidant, anti-inflammatory, immunity, and gut microbiota modulation in mice. J Food Biochem. 2021;45(1):e13567. doi: https://doi.org/10.1111/jfbc.13567Miao F, Shan C, Shah SA, et al. D. Effect of walnut (Juglans sigillata) oil on intestinal antioxidant, anti-inflammatory, immunity, and gut microbiota modulation in mice. J Food Biochem. 2021;45(1):e13567. doi: https://doi.org/10.1111/jfbc.13567Налетов А.В., Хавкин А.И., Мацынин А.Н., Стрионова В.С. Перспективы использования грецких орехов в качестве компонента диетотерапии при воспалительных заболеваниях кишечника // Педиатрическая фармакология. — 2025. — Т. 22. — № 1. — С. 56-61. — doi: https://doi.org/10.15690/pf.v22i1.2853Nalyotov AV, Khavkin AI, Matsynin AN, Strionova VS. Potential of Using Walnuts as a Part of Nutritional Therapy for Inflammatory Bowel Diseases. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2025;22(1):56-61. (In Russ). doi: https://doi.org/10.15690/pf.v22i1.2853Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi: https://doi.org/10.1053/j.gastro.2021.04.063Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi: https://doi.org/10.1053/j.gastro.2021.04.063Cheifetz AS, Abreu MT, Afif W, et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021;116(10):2014-2025. doi: https://doi.org/10.14309/ajg.0000000000001396Cheifetz AS, Abreu MT, Afif W, et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021;116(10):2014-2025. doi: https://doi.org/10.14309/ajg.0000000000001396James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J. 2008;38(2):114-119. doi: https://doi.org/10.1111/j.1445-5994.2007.01601.xJames SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J. 2008;38(2):114-119. doi: https://doi.org/10.1111/j.1445-5994.2007.01601.xQuiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, doubleblind study. J Pediatr Gastroenterol Nutr. 2009;49(5):571-579. doi: https://doi.org/10.1097/MPG.0b013e31819bcac4Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, doubleblind study. J Pediatr Gastroenterol Nutr. 2009;49(5):571-579. doi: https://doi.org/10.1097/MPG.0b013e31819bcac4Jois A, Alex G. Inflammatory Bowel Disease in Children. Indian J Pediatr. 2024;91(5):490-498. doi: https://doi.org/10.1007/s12098-023-04671-0Jois A, Alex G. Inflammatory Bowel Disease in Children. Indian J Pediatr. 2024;91(5):490-498. doi: https://doi.org/10.1007/s12098-023-04671-0Никонов Е.Л., Аксенов В.А., Скворцова Т.А., Жарова М.Е. Иммунотерапия воспалительных заболеваний кишечника // Доктор.Ру. — 2019. — № 10. — С. 31-37. — doi: https://doi.org/10.31550/1727-2378-2019-165-10-31-37Nikonov EL, Aksyonov VA, Skvortsova TA, Zharova ME. Immunotherapy for Inflammatory Bowel Disease. Doctor.Ru. 2019;(10):31-37. (In Russ). doi: https://doi.org/10.31550/1727-2378-2019-165-10-31-37Михайлова Т.Л., Макарчук П.А., Головенко О.В., Веселов А.В. Лечение язвенного колита: опыт применения меторексата в ГНЦ колопроктологии // Фарматека. — 2011. — № 2. — С. 47-49.Mikhailova TL, Makarchuk PA, Golovenko OV, Veselov AV. Lechenie yazvennogo kolita: opyt primeneniya metoreksata v GNTs koloproktologii. Farmateka. 2011;(2):47-49. (In Russ).Wang M, Zhao J, Wang H, et al. Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy. Front Pharmacol. 2022;13:996065. doi: https://doi.org/10.3389/fphar.2022.996065Wang M, Zhao J, Wang H, et al. Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy. Front Pharmacol. 2022;13:996065. doi: https://doi.org/10.3389/fphar.2022.996065Jagt JZ, Galestin SE, Claesen J, et al. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study. J Pediatr Gastroenterol Nutr. 2023;77(3):373-380. doi: https://doi.org/10.1097/MPG.0000000000003865Jagt JZ, Galestin SE, Claesen J, et al. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study. J Pediatr Gastroenterol Nutr. 2023;77(3):373-380. doi: https://doi.org/10.1097/MPG.0000000000003865Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71-72:1-12. doi: https://doi.org/10.1016/j.cytogfr.2023.07.001Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71-72:1-12. doi: https://doi.org/10.1016/j.cytogfr.2023.07.001Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an openlabel multicentre randomised controlled trial. Gut. 2022;71(1):34-42. doi: https://doi.org/10.1136/gutjnl-2020-322339Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an openlabel multicentre randomised controlled trial. Gut. 2022;71(1):34-42. doi: https://doi.org/10.1136/gutjnl-2020-322339Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease. Ann Gastroenterol. 2018;31(4):413-424. doi: https://doi.org/10.20524/aog.2018.0253Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease. Ann Gastroenterol. 2018;31(4):413-424. doi: https://doi.org/10.20524/aog.2018.0253Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric Crohn's disease: a three-year followup. Pediatr Gastroenterol Hepatol Nutr. 2012;15(4):243-249. doi: https://doi.org/10.5223/pghn.2012.15.4.243Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric Crohn's disease: a three-year followup. Pediatr Gastroenterol Hepatol Nutr. 2012;15(4):243-249. doi: https://doi.org/10.5223/pghn.2012.15.4.243Kapizioni C, Desoki R, Lam D, et al. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790-800. doi: https://doi.org/10.1093/ecco-jcc/jjad203Kapizioni C, Desoki R, Lam D, et al. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790-800. doi: https://doi.org/10.1093/ecco-jcc/jjad203Scarallo L, Bolasco G, Barp J, et al. Anti-Tumor Necrosis FactorAlpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis. 2022;28(2):183-191. doi: https://doi.org/10.1093/ibd/izab046Scarallo L, Bolasco G, Barp J, et al. Anti-Tumor Necrosis FactorAlpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis. 2022;28(2):183-191. doi: https://doi.org/10.1093/ibd/izab046Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2019;12(1):1-9. doi: https://doi.org/10.1007/s12328-018-0906-9Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2019;12(1):1-9. doi: https://doi.org/10.1007/s12328-018-0906-9Ylisaukko-Oja T, Puttonen M, Jokelainen J, et al. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol. 2022;57(4):415-423. doi: https://doi.org/10.1080/00365521.2021.2014950Ylisaukko-Oja T, Puttonen M, Jokelainen J, et al. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol. 2022;57(4):415-423. doi: https://doi.org/10.1080/00365521.2021.2014950Chavannes M, Martinez-Vinson C, Hart L, et al. Management of paediatric patients with medically refractory Crohn's disease using ustekinumab: A multi-centred cohort study. J Crohns Colitis. 2019;13(5):578-84. doi: https://doi.org/10.1093/ecco-jcc/jjy206Chavannes M, Martinez-Vinson C, Hart L, et al. Management of paediatric patients with medically refractory Crohn's disease using ustekinumab: A multi-centred cohort study. J Crohns Colitis. 2019;13(5):578-84. doi: https://doi.org/10.1093/ecco-jcc/jjy206Ledder O, Assa A, Levine A, et al. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience from the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230-1237. doi: https://doi.org/10.1093/ecco-jcc/jjx082Ledder O, Assa A, Levine A, et al. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience from the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230-1237. doi: https://doi.org/10.1093/ecco-jcc/jjx082Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66(2):199-209. doi: https://doi.org/10.1136/gutjnl-2016-312912Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66(2):199-209. doi: https://doi.org/10.1136/gutjnl-2016-312912Tanida S, Mizoshita T, Ozeki K, et al. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7(2):118-121. doi: https://doi.org/10.14740/jocmr1991wTanida S, Mizoshita T, Ozeki K, et al. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7(2):118-121. doi: https://doi.org/10.14740/jocmr1991wvan Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. doi: https://doi.org/10.1056/NEJMoa1205037van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. doi: https://doi.org/10.1056/NEJMoa1205037Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi: https://doi.org/10.1016/S0140-6736(17)30182-4Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi: https://doi.org/10.1016/S0140-6736(17)30182-4Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):213-224. doi: https://doi.org/10.1111/apt.14173Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):213-224. doi: https://doi.org/10.1111/apt.14173Imdad A, Pandit NG, Zaman M, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4(4):CD012774. doi: https://doi.org/10.1002/14651858.CD012774.pub3Imdad A, Pandit NG, Zaman M, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4(4):CD012774. doi: https://doi.org/10.1002/14651858.CD012774.pub3Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19(4):431-438. doi: https://doi.org/10.1080/1744666X.2023.2185605Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19(4):431-438. doi: https://doi.org/10.1080/1744666X.2023.2185605Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory Bowel Diseases and Gut Microbiota. Int J Mol Sci. 2023;24(4):3817. doi: https://doi.org/10.3390/ijms24043817Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory Bowel Diseases and Gut Microbiota. Int J Mol Sci. 2023;24(4):3817. doi: https://doi.org/10.3390/ijms24043817Лобаков А.И., Филижанко В.Н., Богомазов Ю.К. и др. Результаты хирургического лечения осложненных форм воспалительных заболеваний кишечника // Колопроктология. — 2011. — № S3. — С. 130-131.Lobakov AI, Filizhanko VN, Bogomazov YuK, et al. Rezul'taty khirurgicheskogo lecheniya oslozhnennykh form vospalitel'nykh zabolevanii kishechnika. Koloproktologiya. 2011;(S3):130-131. (In Russ).Ullrich SJ, Frischer JS. Surgical management of complicated Crohn's disease. Semin Pediatr Surg. 2024;33(2):151399. doi: https://doi.org/10.1016/j.sempedsurg.2024.151399Ullrich SJ, Frischer JS. Surgical management of complicated Crohn's disease. Semin Pediatr Surg. 2024;33(2):151399. doi: https://doi.org/10.1016/j.sempedsurg.2024.151399Bachour SP, Click BH. Clinical Update on the Prevention and Management of Postoperative Crohn's Disease Recurrence. Curr Gastroenterol Rep. 2024;26(2):41-52. doi: https://doi.org/10.1007/s11894-023-00911-7Bachour SP, Click BH. Clinical Update on the Prevention and Management of Postoperative Crohn's Disease Recurrence. Curr Gastroenterol Rep. 2024;26(2):41-52. doi: https://doi.org/10.1007/s11894-023-00911-7Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2018;12(1):1-16. doi: https://doi.org/10.1093/ecco-jcc/jjx061Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2018;12(1):1-16. doi: https://doi.org/10.1093/ecco-jcc/jjx061Яблокова Е.А., Хавкин А.И., Лохматов М.М. и др. Предикторы хирургического вмешательства в дебюте стенозирующей болезни Крона у подростка 15 лет // Экспериментальная и клиническая гастроэнтерология. — 2022. — № 6. — С. 171-177. — doi: https://doi.org/10.31146/1682-8658-ecg-202-6-171-177Yablokova EA, Khavkin AI, Lokhmatov MM, et al. Predictors of surgical intervention in the onset of stenotic Crohn's disease in a 15-year-old teenager. Experimental and Clinical Gastroenterology. 2022;(6):171-177. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-202-6-171-177Поддубный И.В., Алиева Э.И., Сытьков В.В. и др. Плановые лапароскопические резекции кишечника у детей с болезнью Крона // Вопросы практической педиатрии. — 2023. — Т. 18. — № 4. — С. 13-19. — doi: https://doi.org/10.20953/1817-7646-2023-4-13-19Poddubny IV, Alieva EI, Sytkov VV, et al. Elective laparoscopic bowel resections in children with Crohn's disease. Voprosy prakticheskoi pediatrii = Clinical Practice in Pediatrics. 2023;18(4):13-19. (In Russ). doi: https://doi.org/10.20953/1817-7646-2023-4-13-19Boscarelli A, Bramuzzo M. Pediatric stricturing Crohn's disease. World J Gastroenterol. 2024;30(12):1651-1654. doi: https://doi.org/10.3748/wjg.v30.i12.1651Boscarelli A, Bramuzzo M. Pediatric stricturing Crohn's disease. World J Gastroenterol. 2024;30(12):1651-1654. doi: https://doi.org/10.3748/wjg.v30.i12.1651Newton C, Fichera A. Anastomosis after Bowel Resection for Crohn's Disease: State of the Art Review. Clin Colon Rectal Surg. 2024;38(2):104-112. doi: https://doi.org/10.1055/s-0044-1786534Newton C, Fichera A. Anastomosis after Bowel Resection for Crohn's Disease: State of the Art Review. Clin Colon Rectal Surg. 2024;38(2):104-112. doi: https://doi.org/10.1055/s-0044-1786534Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. Dis Colon Rectum. 2022;65(8):964-985. doi: https://doi.org/10.1097/DCR.0000000000002473Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. Dis Colon Rectum. 2022;65(8):964-985. doi: https://doi.org/10.1097/DCR.0000000000002473Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Ионов А.Л. Выбор оптимальной стратегии лечения детей с болезнью Крона и кроноподобными иммунодефицитами с перианальными поражениями // Вопросы детской диетологии. — 2019. — Т. 17. — № 1. — С. 7-16. — doi: https://doi.org/10.20953/1727-5784-2019-1-7-16Shcherbakova OV, Razumovskiy AYu, Shumilov PV, Ionov AL. The choice of the optimal strategy for treatment of children with Crohn's disease and Crohn-like immunodeficiencies with perianal lesions. Voprosy detskoi dietologii = Pediatric Nutrition. 2019;17(1):7-16. (In Russ). doi: https://doi.org/10.20953/1727-5784-2019-1-7-16Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Сытьков В.В. Хирургические подходы к лечению детей и подростков с перианальной болезнью Крона // Вестник хирургической гастроэнтерологии. — 2019. — № 4. — С. 45-55.Shcherbakova OV, Razumovskiy AY, Shumilov PV, Sytkov VV. Surgical Approaches to the Treatment of Children and Adolescents with Perianal Crohn's Disease. Vestnik khirurgicheskoi gastroenterologii. 2019;(4):45-55. (In Russ).Hansen R, Meade S, Beattie RM, et al. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2021;70(6):1044-1052. doi: https://doi.org/10.1136/gutjnl-2020-322449Hansen R, Meade S, Beattie RM, et al. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2021;70(6):1044-1052. doi: https://doi.org/10.1136/gutjnl-2020-322449Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):292-310. doi: https://doi.org/10.1097/MPG.0000000000002036Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):292-310. doi: https://doi.org/10.1097/MPG.0000000000002036Ochoa B, McMahon L. Surgery for ulcerative colitis. Semin Pediatr Surg. 2024;33(2):151404. doi: https://doi.org/10.1016/j.sempedsurg.2024.151404Ochoa B, McMahon L. Surgery for ulcerative colitis. Semin Pediatr Surg. 2024;33(2):151404. doi: https://doi.org/10.1016/j.sempedsurg.2024.151404Marzo RR, Bhattacharya S, Ujang NB, et al. The impact of service quality provided by health-care centers and physicians on patient satisfaction. J Educ Health Promot. 2021;10:160. doi: https://doi:10.4103/jehp.jehp_979_20Marzo RR, Bhattacharya S, Ujang NB, et al. The impact of service quality provided by health-care centers and physicians on patient satisfaction. J Educ Health Promot. 2021;10:160. doi: https://doi:10.4103/jehp.jehp_979_20Tham SW, Rollins MD, Reeder RW, et al. Health-related quality of life in children with Hirschsprung disease and children with functional constipation: Parent-child variability. J Pediatr Surg. 2022;57(8):1694-1700. doi: https://doi:10.1016/j.jpedsurg.2022.04.009Tham SW, Rollins MD, Reeder RW, et al. Health-related quality of life in children with Hirschsprung disease and children with functional constipation: Parent-child variability. J Pediatr Surg. 2022;57(8):1694-1700. doi: https://doi:10.1016/j.jpedsurg.2022.04.009Park SK, Ko BM, Goong HJ, et al. Short health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(19):3530-3537. doi: https://doi.org/10.3748/wjg.v23.i19.3530Park SK, Ko BM, Goong HJ, et al. Short health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(19):3530-3537. doi: https://doi.org/10.3748/wjg.v23.i19.3530Vanhelst J, Beghin L, Drumez E, et al. Validation of the IMPACT-III Questionnaire in French Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(4):e71-e76. doi: https://doi.org/10.1097/MPG.0000000000003716Vanhelst J, Beghin L, Drumez E, et al. Validation of the IMPACT-III Questionnaire in French Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(4):e71-e76. doi: https://doi.org/10.1097/MPG.0000000000003716Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85-90. doi: https://doi: https://doi.org/10.1016/j.jpeds.2014.08.022Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85-90. doi: https://doi: https://doi.org/10.1016/j.jpeds.2014.08.022Tan YH, Siew JX, Thomas B, Ng KC. Patient-reported outcome measures and value-based medicine in paediatrics: a timely review. Singapore Med J. 2023;64(5):285-293. doi: https://doi:10.11622/smedj.2021102Tan YH, Siew JX, Thomas B, Ng KC. Patient-reported outcome measures and value-based medicine in paediatrics: a timely review. Singapore Med J. 2023;64(5):285-293. doi: https://doi:10.11622/smedj.2021102Аракелян А.Л., Сурков А.Н., Баранов А.А. и др. Лингвистическая корректность и достоверность содержания русской версии модуля гастроинтестинальных симптомов опросника PedsQL™ для пациентов педиатрического профиля // Педиатрическая фармакология. — 2023. — Т. 20. — № 2. — С. 112-119. — doi: https://doi.org/10.15690/pf.v20i2.2553Arakelyan AL, Surkov AN, Baranov AA, et al. Linguistic accuracy and authenticity of the content of the Russian version of the module of gastrointestinal symptoms of the PedsQL™ questionnaire for pediatric patients. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2023;20(2):112-119. (In Russ). https://doi.org/10.15690/pf.v20i2.2553

The authors declare that there are no conflicts of interest present.